Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting

P. Diemunsch, G. P. Joshi, J. F. Brichant

Research output: Contribution to journalReview articlepeer-review

81 Scopus citations


Despite major advances, emesis remains a major problem in the context of cancer chemotherapy and in the postoperative period. A better understanding of the relevant neurocircuitry, especially the central pattern generator responsible for emesis and the central role of substance P, led to the development of a new class of antiemetics: the neurokinin-1 (NK1) receptor antagonists. Aprepitant is the first NK1 receptor antagonist approved for use in postoperative nausea and vomiting, but several other compounds are currently being investigated for their potential as antiemetics in the postoperative and cancer chemotherapy settings.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalBritish Journal of Anaesthesia
Issue number1
StatePublished - Jul 2009


  • Antagonists, NK1 receptor, aprepitant
  • Complications
  • Substance P
  • Vomiting, nausea

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting'. Together they form a unique fingerprint.

Cite this